Daiichi Sankyo Presents New ADC Cancer Research at WCLC and ESMO

Daiichi Sankyo is set to present new clinical research findings from its antibody-drug conjugate (ADC) portfolio at two major conferences: the IASLC 2024 World Conference on Lung Cancer and the 2024 European Society for Medical Oncology. More than 25 abstracts covering various cancer types will be showcased, highlighting the company's ongoing efforts to establish new care standards for cancer patients.

Six late-breaking presentations are particularly noteworthy. Among them, two back-to-back presentations during Presidential Symposium 1 at the IASLC conference will feature interim results from the NeoCOAST-2 phase 2 trial, which is evaluating novel perioperative treatment combinations. One specific arm of the study focuses on using datopotamab deruxtecan along with durvalumab and chemotherapy as a neoadjuvant treatment, followed by adjuvant treatment with durvalumab in patients with early-stage non-small cell lung cancer (NSCLC).

Additionally, the symposium will present findings from the TROPION-Lung01 phase 3 trial, which compares datopotamab deruxtecan to docetaxel in patients with advanced NSCLC. These include overall survival results as well as the application of AstraZeneca’s quantitative continuous scoring platform to measure TROP2 in tissue samples.

Other significant data to be presented at the IASLC event include interim results from the IDeate-Lung01 phase 2 trial involving ifinatamab deruxtecan in patients with pretreated extensive-stage small cell lung cancer. Results from the DESTINY-Lung03 phase 1b trial of trastuzumab deruxtecan in previously treated HER2-overexpressing NSCLC will also be discussed. A poster from a phase 1b trial evaluating the combination of datopotamab deruxtecan and valemetostat in advanced NSCLC will provide further insights.

At the European Society for Medical Oncology conference, several presentations will emphasize Daiichi Sankyo's progress in lung cancer treatment. These include a post-hoc analysis of patients with NSCLC and brain metastases from the TROPION-Lung01 trial and intracranial responses in the IDeate-Lung01 trial of ifinatamab deruxtecan. Another trial-in-progress poster will explore the design of the IDeate-Lung03 phase 1b/2 trial for combination treatments in extensive-stage small cell lung cancer.

In breast cancer research, late-breaking presentations at ESMO will include primary results from the DESTINY-Breast12 phase 3b/4 trial, evaluating ENHERTU in patients with advanced breast cancer, and data from the DESTINY-Breast06 phase 3 trial, focusing on HER2 low and ultralow status in metastatic breast cancer. Additional presentations will cover patient-reported outcomes, safety and biomarker analysis from various trials, including the ICARUS-BREAST01 and ERICA trials.

Moreover, a proffered paper session will present preliminary results from a phase 1 trial of DS-9606, an ADC targeting CLDN6 in solid tumors. Results from the DESTINY-Gastric03 phase 1b/2 trial, which evaluates ENHERTU monotherapy or in combination with chemotherapy and immunotherapy in gastric cancer, will also be featured. Furthermore, the TROPION-PanTumor03 phase 2 trial results for datopotamab deruxtecan in endometrial or ovarian cancer will be highlighted.

Daiichi Sankyo's portfolio consists of seven ADCs in clinical development, built on two unique ADC technology platforms. The first platform includes ENHERTU and datopotamab deruxtecan, among others, which are developed in collaboration with AstraZeneca and Merck. The second platform features ADCs like DS-9606, using a modified pyrrolobenzodiazepine payload. Although these investigational drugs have not yet been approved, they represent significant advancements in targeting various cancer types.

With over 120 years of experience, Daiichi Sankyo continues to leverage its scientific and technological expertise to develop innovative treatments for cancers and other diseases with unmet medical needs. The company remains committed to improving global healthcare standards and enhancing the quality of life for patients worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!